Last reviewed · How we verify
NCT06916975: CSPAC-48
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 trial testing Adebrelimab in Pancreatic Cancer Non-resectable in 46 participants. Not yet recruiting.
1 December 2027
Quick facts
| Lead sponsor | Jin Xu |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 15 April 2025 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Adebrelimab — full drug profile →
- AG
Conditions studied
- Pancreatic Cancer Non-resectable — all drugs for Pancreatic Cancer Non-resectable →
- Pancreatic Cancer Metastatic — all drugs for Pancreatic Cancer Metastatic →
Sponsor
Jin Xu
Who can join
Adults 18 to 75, any sex, with Pancreatic Cancer Non-resectable or Pancreatic Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic therapy but have not undergone gemcitabine-based treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06916975
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Adebrelimab
Trials testing the same drug.
- NCT07398560 — Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lu · Phase 2 · not yet recruiting
- NCT07392541 — Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer · Phase 1, PHASE2 · recruiting
- NCT07266025 — Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-Hi · Phase 2 · not yet recruiting
- NCT06177522 — Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07241793 — Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metast · Phase 2 · recruiting
Other recruiting trials for Pancreatic Cancer Non-resectable
Currently open trials in the same condition.
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT06937996 — Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System- · recruiting
- NCT07066995 — Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT06840067 — Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer. · NA · recruiting
- NCT07271823 — Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06916975 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jin Xu
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06916975.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing